AUG 14, 2026 · PHASE 2 TRIAL
Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients
ClinicalTrials.gov
Phase 2 trial with minimal enrollment (5 participants) in a population intolerant of concurrent chemoradiation; no results are posted in this registry record.
Reported
Planned enrollment5
Primary outcome measureProgression-free survival at 6 months after…
PhasePHASE 2